Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Third Generation TKI”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05601973
What this trial is testing

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Who this might be right for
Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation 60
Not applicableNot Yet RecruitingNCT07686185
What this trial is testing

A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.

Who this might be right for
Non-Small Cell Lung CancerAdjuvant Therapy
First Affiliated Hospital of Guangxi Medical University 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07822984
What this trial is testing

Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy

Who this might be right for
EGFR-mutant Non-small Cell Lung CancerSBRTNSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University 374
Testing effectiveness (Phase 2)Looking for participantsNCT06652048
What this trial is testing

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Who this might be right for
Non-Small Cell Lung Cancer
Jialei Wang 60
Large-scale testing (Phase 3)Looking for participantsNCT07155187
What this trial is testing

Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 490
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06452433
What this trial is testing

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 91
Testing effectiveness (Phase 2)Looking for participantsNCT05994131
What this trial is testing

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Who this might be right for
NSCLC
InxMed (Shanghai) Co., Ltd. 110
Testing effectiveness (Phase 2)Looking for participantsNCT06453902
What this trial is testing

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Who this might be right for
Chronic Myeloid LeukemiaAccelerated Phase CML
Shenzhen TargetRx Co., Ltd. 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06634667
What this trial is testing

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 30
Very early researchLooking for participantsNCT07074496
What this trial is testing

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Who this might be right for
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06441045
What this trial is testing

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Who this might be right for
Leptomeningeal Metastasis
Fujian Cancer Hospital 112
Early research (Phase 1)Not Yet RecruitingNCT07461727
What this trial is testing

An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

Who this might be right for
Non-Small Cell Lung CancerMetastatic Non-small Cell Lung CancerLiver Metastases+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT06020066
What this trial is testing

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Who this might be right for
Brain MetastasesNon-small Cell Lung Cancer
Fudan University 202
Not applicableUnknownNCT02738593
What this trial is testing

Detection Cell Free DNA in Lung Cancer Patients

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 124
Not applicableLooking for participantsNCT07542210
What this trial is testing

Barriers and Facilitators of Persistence With Adjuvant Osimertinib

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 100
Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07551414
What this trial is testing

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

Who this might be right for
NSCLC (Non-small Cell Lung Carcinoma)Leptomeningeal MetastasisEGFR-TKI Sensitizing Mutation+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 38
Testing effectiveness (Phase 2)Looking for participantsNCT07181499
What this trial is testing

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Who this might be right for
NSCLCAdjuvant Drug TherapyEGFR
Betta Pharmaceuticals Co., Ltd. 28
Not applicableLooking for participantsNCT06604689
What this trial is testing

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastasases
Fudan University 800